Daniel S. Chen
107 works · 46,353 citations · h-index 38
Top works
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Elements of cancer immunity and the cancer–immune set point
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
- VEGF in Signaling and Disease: Beyond Discovery and Development
- Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes.
- Top 10 Challenges in Cancer Immunotherapy
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- Combinations of Bevacizumab With Cancer Immunotherapy
- T cells use two directionally distinct pathways for cytokine secretion
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy